Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
genetic associations Adding a data source to the Open Targets Platform: an update In this post, I will give you an update on how to add a new data source to the Open Targets Platform following parts 1 and 2 published in 2018.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.
Open Targets Platform Open Targets Platform: release 19.02 is out Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.
Open Targets Looking for cell line models to predict drug response in cancer patients? On this World Cancer Day, Hanna writes about Cellector, an open source tool for the selection of clinically relevant cancer cell lines for in vitro experiments.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. It's D-time.
Open Targets Platform From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Third in the series is C.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. Second in the series is B.
release notes Open Targets Platform: what's new in our latest release Our latest release of the Open Targets Platform is out. More targets, more evidence, more target-disease associations and a new prioritisation view.
Open Targets From antibody to zinc finger: an A-Z of Open Targets As users discover our freely available resources, it’s time to take a closer look at the lexicon of terms that matter to Open Targets. First in the series is A.
Open Targets Platform We have a new release of the Open Targets Platform The latest version of the Open Targets Platform is out. Why not check the new target-disease associations and the new chemical probes we have to offer?
Open Targets Platform Everything you need to know about the new GWAS Catalog Open Targets is investing in a new project to expand the scope of the GWAS Catalog to include targeted arrays, such as MetaboChip and ImmunoChip.
Europe PMC How Europe PMC can help you find associations between genes and diseases Open Targets Q&A on how you can stay up-to-date with the latest advances in drug discovery.
release notes The latest release of the Open Targets Platform is out! We have a new release of the Open Targets Platform. New data source for target-disease associations, new drug visualisations, cancer biomarkers, and more.
Open Targets Touring with Takeda Following Takeda joining Open Targets in December 2017, I set off to Takeda in the US and Japan for a series of workshops.
Open Targets Open Targets Platform: we have a new release The latest release of Open Targets Platform is out. We now have the cancer hallmarks, targeted association studies, a YouTube channel and much more.
Open Targets How to predict the success of drug development If you are attending BioData World West 2018 in San Francisco, come one day earlier and join our training sessions, a workshop and a datathon.
Open Targets How CRISPR will guide the way to better cancer therapies Fiona Behan tells us why she works in cancer research with Open Targets and how CRISPR/Cas9 has revolutionised the fight against cancer.
LINK Introducing LINK: the Open Targets Literature Knowledge Graph Explore half a billion relations between genes, diseases, drugs and key concepts extracted from PubMed abstracts using NLP (Natural Language Processing).
Open Targets Translation, Translation, Translation Over the last 14 days, we have had two scientific meetings taking place right here on the Wellcome Genome Campus, the Translational Bioinformatics conference and the Translational Target Validation symposium. What did they
targetvalidation.org Direct versus indirect evidence: should you care? The latest release of our Open Targets Platform contains 5.1 million pieces of evidence for target-disease associations. Where does this evidence come from? How do we integrate the different evidence types? Our
Open Targets Open Targets - First Impressions I recently joined the Open Targets Consortium as Operations Director. This moved me from almost the very end of the R&D pipeline where I had been working on processes for small
targetvalidation.org What do we have in store for you in the run up to Christmas? The latest release of our Open Targets Platform is out. We have plenty of new web features and new data to help your journey into drug discovery. These are our latest stats: 31,
targetvalidation.org An approach to visualising pathway evidence The starting point in drug discovery is often a specific target or disease. But what if instead you have a specific pathway to start with? As part of an Open Targets research project
targetvalidation.org Did you see the latest version of Open Targets Platform? That's right. The Open Targets Platform v1.2 is out! In this release, we have new web displays and plenty of extra data to assist you in drug discovery and validation: 30,591
